ImmunityBio (IBRX) Depreciation & Amortization (CF) (2014 - 2026)

ImmunityBio (IBRX) has reported Depreciation & Amortization (CF) for 13 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 14.39% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $16.1 million (down 4.47% YoY), while the FY2025 annual figure was $15.5 million, down 11.56% from the prior year.
• Depreciation & Amortization (CF) rose to $4.4 million in Q1 2026 per IBRX's latest filing, from $3.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.2 million in Q4 2022 and bottomed at $3.8 million in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $4.4 million across 5 years, with a median of $4.4 million in 2022.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 45.37% — and 2025, when it retreated 15.94%.
• ImmunityBio's Depreciation & Amortization (CF) stood at $5.2 million in 2022, then dropped by 12.67% to $4.6 million in 2023, then dropped by 9.33% to $4.1 million in 2024, then retreated by 6.6% to $3.9 million in 2025, then climbed by 13.32% to $4.4 million in 2026.
• Business Quant data shows IBRX's Depreciation & Amortization (CF) at $4.4 million in Q1 2026, $3.9 million in Q4 2025, and $4.0 million in Q3 2025.